Company intelligence / Profile preview

Clover Network

Chengdu, Sichuan, Chinaclover.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clover Biopharmaceuticals has commercialized a quadrivalent seasonal influenza vaccine in China and advanced multiple next-generation respiratory combination vaccines into clinical trials. Its RSV candidate SCB‑1019 has shown positive head-to-head data versus GSK’s AREXVY. The company leverages its proprietary Trimer‑Tag platform to develop innovative subunit vaccines targeting major respiratory viruses.

Therapeutic areas: Infectious Diseases
Modalities: Protein subunit vaccineRecombinant proteinVaccineBiologic
Industry: Biotech

Partnerships

Keyuan Xinhai Medical Products Trading Co. Ltd. (“Kyuan Trade”)—distribution partner in China for AdimFlu-S [QIS]global partnerships with organizations not individually named

Beyond the preview

Go deeper on Clover Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clover Network.

Explore the full profile